I routinely see trials run with ‘not the best’ SOC + new drug… because if the best SOC was used there would be no benefit to measure. #unethical

Glad this issue is getting some attention: Clinical trial control arms that are not the best SOC

Plz check out our new paper on pre-op SRS and the immune microenvironment of human brain metastases. nature.com/articles/s4146… Big team effort: Carey Jansen, MD PhD Meghana Pagadala MD PhD Haydn Kissick Maria Andrea Cardenas Mohammad K. Khan, MD and many more.

Great to be back in San Diego working on advances in Translational Medicine!

One of the hardest things I do in #oncology clinic is translate results from a clinical trial to the #patient in front of me. In Nature Medicine, we introduce TrialTranslator, a #machinelearning framework for individualized #cancer trial emulation. nature.com/articles/s4159…

Congrats!

LEAP-012: TACE +/- lenvima/pembro for intermediate risk HCC. -No difference in OS -Grade 3+ AE 71% in combo arm, and 32% with TACE alone (!!) IMO this is not an effective, cost-effective, or “well-tolerated” regimen.

This is great work and just the start for using foundation models to understand gene expression networks!

Great presentations and outstanding attendance. Thanks to Midhun Malla for organizing and for our speakers Aparna Raj Parikh kavi Mehmet Akce, MD UAB O'Neal Comprehensive Cancer Center #uab_cci_gioncsymposium_2025

Important recent Annals of Surgical Oncology study from WashU Medicine Department of Surgery looking retrospectively at long-term outcomes of near-complete responses who undergo #WatchAndWait for rectal cancer. Almost all patients received SCRT followed by consolidation chemo-->48% cCR, 28% near-complete (NCR), and

Excellent work by V.PhD Numenos using machine learning to understand checkpoint inhibitor resistance!

Have no respect whatsoever for authority; forget who said it and instead look what he starts with, where he ends up, and ask yourself, "Is it reasonable?"

Shout out to Udbhav Ram for his 1st first-authored publication! Great collaboration between McMaster University and UAB Heersink School of Medicine, we look forward to having you back in BHM this summer! UAB Radiation Oncology UAB Medical Physics UAB Heersink Institute for Biomedical Innovation Rubin Pillay

This has been a long-time coming. Want to acknowledge the great team i got to work with on this project where we looked at funding of radiation oncology research from the NIH. sciencedirect.com/science/articl…

This is a good initiative. Will be contributing in the AI clinical trials space (AI-enabled patient eligibility decisions using phase 2 to design better phase 3 trials).

Incredible AI work showcased @ AWS Life Sciences Symposium in NYC today. Real advances in preclinical through clinical implementation. Significant venture presence too, looking for unicorns! Amazon Web Services

Genentech’s head of research and early development Aviv Regev explains what AI is bad at: thinking for a long time. Genentech #STATBreakthrough

👏 Huge congratulations to Dr. Neil Pfister (@UABRadOnc) for his invited lecture at the 17th Wolfsberg Meeting on “Ionizing radiation-induced oxidative stress and PARP-dependent mitochondrial signaling”! 🌟 We are incredibly proud to have him on faculty at UAB Heersink School of Medicine, driving

Incredible science and stellar presentations from @UABRadOnc at the Wolfsberg Meeting! 💥 From FLASH proton therapy to immunoradiosensitization and molecular targeting, our team is showcasing cutting-edge work that’s pushing the field forward. Proud to be part of this amazing

Excited to present our work @ the 2nd annual Roche CGB summit in Basel